Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients.
Numerous studies conducted in different countries and in different populations of patients on dialysis have consistently documented that a large proportion of such patients carry Staphylococcus aureus in their nares and that the risk of them becoming infected with their own strains is quite high. Furthermore, S. aureus infections can cause considerable morbidity and mortality in these patients. Thus, decolonization of the nares may prevent S. aureus infections and the attendant complications. The published data that support the use of rifampicin, intranasal mupirocin and povidone-iodine to prevent S. aureus infections in patients on dialysis are reviewed in detail.
Herwaldt
L A
LA
University of Iowa College of Medicine, Iowa City 52242-1081, USA. loreen-herwaldt@uiowa.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002353:Carrier State / Q000382:microbiology*; D003362:Cost-Benefit Analysis; D006801:Humans; D016712:Mupirocin / Q000627:therapeutic use; D009666:Nose / Q000382:microbiology*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D011206:Povidone-Iodine / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000209:etiology / Q000517:prevention & control*; D013211:Staphylococcus aureus
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D011206:Povidone-Iodine; D016712:Mupirocin; D012293:Rifampin